Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cascadian Therapeutics Inc (NASDAQ:CASC)

4.16
Delayed Data
As of Mar 27
 +0.08 / +1.96%
Today’s Change
3.49
Today|||52-Week Range
10.98
-3.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$200.8M

Company Description

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company, engages in the development of therapeutic products for the treatment of cancer. Its lead product candidate ONT-380, is an orally active and selective small-molecule HER2 inhibitor. It also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Seattle, WA.

Contact Information

Cascadian Therapeutics, Inc.
2601 4th Avenue
Seattle Washington 98121
P:(206) 801-2100
Investor Relations:
(206) 801-2107

Employees

Shareholders

Mutual fund holders6.89%
Other institutional28.35%
Individual stakeholders20.11%

Top Executives

Scott D. MyersPresident, Chief Executive Officer & Director
Gary W. ChristiansonChief Operating Officer
Julia Marie EastlandCFO, Secretary & VP-Corporate Development
Scott Robert PetersonChief Scientific Officer
Luke N. WalkerVice President-Clinical Development